May 12/2015 FocusNew European Guidelines to Tackle Controversial HTA Components EUnetHTA has developed guidelines to help “set a general framework for EUnetHTA on how to conduct economic evaluations”, arguably most controversial element of health technology assessment (HTA). Leela Barham reports .../Read more/ |
||||||||||
| Focus Edging Through Europe’s HTA Jungle “Tell me what your drug is worth and I’ll tell you what you can charge” used to be to approach that pricing and reimbursement authorities took when a company came onto the market with a new medicine. It was rarely an easy exchange, but it was relatively direct. Not any more, thanks to the rise of HTA, writes Reflector .../Read more/ |
||||||||||
| Emerging Markets South African Start-Ups: Bridging the “Valley of Death” South Africa may have the most developed market for biopharmaceuticals on the African continent, but there are a few critical shortcomings, writes William Looney ... /Read more/ |
||||||||||
| Latin America Scott Lewin looks at Brazil's recently expanded transparency inititatives and how they affect pharma companies doing business in the region ... /Read more/ |
||||||||||
| Special Feature Pharm Exec’s 2015 Brand of the Year How Sovalda and Harvoni reversed expectations around the listless product launch and revived industry reputation for startling breakthrough innovations .../Read more/ |
||||||||||
industry update
|
 |
|
 |
|
|
|
 |
 |
 |
 |
 |
 |